New drug trial aims to tame rare 'Body-on-Fire' disease with fewer steroids

This study compares a newer drug, mepolizumab, against standard steroid-based treatment for people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease. It aims to see if the new approach can better control disease flares and allow patients to use much lower doses of steroids, which cause significant side effects. The trial is enrolling 100 adults with active EGPA to see which treatment strategy is more effective for achieving and maintaining remission.